Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2018
Price : $35 *
At a glance
- Drugs Umirolimus (Primary) ; Zotarolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BATTLE-IN-MULTI
- 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
- 30 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020.